MEDLINE Journals

    Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.

    Authors

    Urban C, Mariano N, Rahal JJ, et al. 

    Institution

    Infectious Diseases Section The New York Hospital Medical Center of Queens Flushing, New York.

    Source

    Antimicrob Agents Chemother 2001 Mar; 45(3) :994-5.

    Language

    eng

    Pub Type(s)

    Journal Article

    PubMed ID

    16557680

    Content Manager
    Related Content

    		Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.

    		Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action.

    		In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore.

    		[Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].

    		Activities of polymyxin B and cecropin A-,melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii.

    		Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

    		Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam.

    		In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases.